Obese individuals with at least one metabolic risk factor (fasting blood sugar = 100, triglycerides = 150, HDL (< 40 mg/dL in men, < 50 mg/dL in women), and insulin = 15)..
Conditions
Interventions
Intervention 1: Intervention group: Participants who are randomly assigned to the personalized diet group will receive a diet tailored to their metabolic pattern. In this study, the predefined Criteri
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: Women and men aged 18-59 years Body mass index 30-40 kg/m Waist circumference more than 90 cm in women and more than 95 cm in men Having at least one metabolic risk factor (fasting blood sugar = 100, triglycerides = 150, HDL (< 40 mg/dL in men, < 50 mg/dL in women) and insulin = 15) Consent to participate in the study
Exclusion criteria
Exclusion criteria: The presence of any disease or condition that affect the person's metabolism and food intake, such as: cancer, irritable bowel syndrome, thyroid disorders, inflammatory bowel diseases, diabetes, hypertension, etc Taking any medication affects the outcomes of the study, such as: blood sugar-lowering drugs, blood lipid-lowering drugs, chromium, omega-3, curcumin, etc Any food allergies or food intolerances Following a special diet such as low calory diets, vegetarian, etc Pregnancy Breastfeeding History of any type of bariatric surgery Weight loss of more than 5% in the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body weight. Timepoint: At baseline (before the start of the intervention), 4 weeks and 12 weeks after initiating the diet. Method of measurement: Body weight scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting Blood Sugar. Timepoint: At baseline (before the start of the intervention) and 12 weeks after initiating the diet. Method of measurement: Glucose Oxidase method.;Serum Insulin. Timepoint: At baseline (before the start of the intervention) and 12 weeks after initiating the diet. Method of measurement: Elisa method.;HOMA-IR. Timepoint: At baseline (before the start of the intervention) and 12 weeks after initiating the diet. Method of measurement: Calculation.;Serum Triglyceride (TG). Timepoint: At baseline (before the start of the intervention) and 12 weeks after initiating the diet. Method of measurement: Enzymatic method.;Low Density lipoprotein Cholesterol (LDL-C). Timepoint: At baseline (before the start of the intervention) and 12 weeks after initiating the diet. Method of measurement: Enzymatic method.;High Density lipoprotein Cholesterol (HDL-C). Timepoint: At baseline (before the start of the intervention) and 12 weeks after initiating the diet. Method of measurement: Enzymatic method.;C-reactive protein quantitive (CRP Quantitive). Timepoint: At baseline (before the start of the intervention) and 12 weeks after initiating the diet. Method of measurement: Elisa method.;Waist circumference. Timepoint: At baseline (before the start of the intervention) and 12 weeks after initiating the diet. Method of measurement: Tape meter.;BMI. Timepoint: At baseline (before the start of the intervention), 4 weeks and 12 weeks after initiating the diet. Method of measurement: Calculation.;Body composition (fat mass, Fat free mass). Timepoint: At baseline (before the start of the intervention), 4 weeks and 12 weeks after initiating the diet. Method of measurement: Body analyzer (InBody 270).;Systolic & diastolic blood pressure. Timepoint: At baseline (before the start of the intervention), 4 weeks and 12 weeks after initiating the diet. Method of measurement: Mercury pressure gauge.;Physical activity assessment. Timepoint: At baseline (before the start of the interven | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSakineh Shab bidar
Tehran University of Medical Sciences
Outcome results
None listed